EP3823636A4 - DOSAGE REGIMEN FOR THE TREATMENT OF COGNITIVE AND MOTOR IMPAIRMENTS WITH BLOOD PLASMA AND BLOOD PLASMA PRODUCTS - Google Patents

DOSAGE REGIMEN FOR THE TREATMENT OF COGNITIVE AND MOTOR IMPAIRMENTS WITH BLOOD PLASMA AND BLOOD PLASMA PRODUCTS Download PDF

Info

Publication number
EP3823636A4
EP3823636A4 EP19838494.3A EP19838494A EP3823636A4 EP 3823636 A4 EP3823636 A4 EP 3823636A4 EP 19838494 A EP19838494 A EP 19838494A EP 3823636 A4 EP3823636 A4 EP 3823636A4
Authority
EP
European Patent Office
Prior art keywords
blood plasma
cognitive
treatment
dosing regimen
motor impairments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19838494.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3823636A1 (en
Inventor
Steven P. Braithwaite
Meghan Kerrisk Campbell
Eva CZIRR
Ian GALLAGER
Nina HUBER
Sam Jackson
S. Sakura Minami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkahest Inc
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Priority to EP23220839.7A priority Critical patent/EP4374921A3/en
Publication of EP3823636A1 publication Critical patent/EP3823636A1/en
Publication of EP3823636A4 publication Critical patent/EP3823636A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP19838494.3A 2018-07-20 2019-07-11 DOSAGE REGIMEN FOR THE TREATMENT OF COGNITIVE AND MOTOR IMPAIRMENTS WITH BLOOD PLASMA AND BLOOD PLASMA PRODUCTS Pending EP3823636A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23220839.7A EP4374921A3 (en) 2018-07-20 2019-07-11 Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862701411P 2018-07-20 2018-07-20
US201862751434P 2018-10-26 2018-10-26
US201962862364P 2019-06-17 2019-06-17
PCT/US2019/041384 WO2020018343A1 (en) 2018-07-20 2019-07-11 Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP23220839.7A Division EP4374921A3 (en) 2018-07-20 2019-07-11 Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products

Publications (2)

Publication Number Publication Date
EP3823636A1 EP3823636A1 (en) 2021-05-26
EP3823636A4 true EP3823636A4 (en) 2022-04-13

Family

ID=69164553

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19838494.3A Pending EP3823636A4 (en) 2018-07-20 2019-07-11 DOSAGE REGIMEN FOR THE TREATMENT OF COGNITIVE AND MOTOR IMPAIRMENTS WITH BLOOD PLASMA AND BLOOD PLASMA PRODUCTS
EP23220839.7A Pending EP4374921A3 (en) 2018-07-20 2019-07-11 Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP23220839.7A Pending EP4374921A3 (en) 2018-07-20 2019-07-11 Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products

Country Status (15)

Country Link
EP (2) EP3823636A4 (ja)
JP (1) JP2021531294A (ja)
KR (1) KR20210024196A (ja)
CN (1) CN112469424A (ja)
AU (1) AU2019306477B2 (ja)
BR (1) BR112021000653A2 (ja)
CA (1) CA3105956A1 (ja)
CL (1) CL2021000118A1 (ja)
CO (1) CO2021000945A2 (ja)
DE (1) DE202019006065U1 (ja)
IL (1) IL279996A (ja)
MA (1) MA53182A (ja)
MX (1) MX2021000707A (ja)
SG (1) SG11202100347QA (ja)
WO (1) WO2020018343A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020378245A1 (en) 2019-11-04 2022-04-07 Alkahest, Inc. Blood plasma fractions for use in muscle regeneration
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
AU2020388572A1 (en) 2019-11-20 2022-05-26 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
EP3906938A1 (en) * 2020-05-07 2021-11-10 Grifols Worldwide Operations Limited Composition comprising albumin for use in the treatment of amyotrophic lateral sclerosis (als) by plasma exchange
US20230285644A1 (en) * 2022-03-10 2023-09-14 Terumo Bct, Inc. Integrated code scanning system and apheresis data control method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018034712A1 (en) * 2016-08-18 2018-02-22 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
WO2018200560A1 (en) * 2017-04-26 2018-11-01 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869431A (en) 1973-03-12 1975-03-04 Firestone Tire & Rubber Co Polyamides and their production
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
US5110907A (en) 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
ES2257225B1 (es) 2006-02-17 2007-03-16 Grifols, S.A Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
ES2332846B1 (es) * 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
PL2271382T3 (pl) 2008-04-15 2013-08-30 Grifols Therapeutics Inc Dwuetapowa ultrafiltracja/diafiltracja
US20150061767A1 (en) 2013-08-28 2015-03-05 Texas Instruments Incorporated Telescopic Amplifier with Improved Common Mode Settling
ES2524516B1 (es) 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
US10525107B2 (en) * 2016-08-18 2020-01-07 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018034712A1 (en) * 2016-08-18 2018-02-22 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
WO2018200560A1 (en) * 2017-04-26 2018-11-01 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020018343A1 *

Also Published As

Publication number Publication date
CA3105956A1 (en) 2020-01-23
AU2019306477A1 (en) 2021-02-11
SG11202100347QA (en) 2021-02-25
KR20210024196A (ko) 2021-03-04
MA53182A (fr) 2021-05-26
DE202019006065U1 (de) 2024-06-24
IL279996A (en) 2021-03-01
CL2021000118A1 (es) 2021-07-30
EP3823636A1 (en) 2021-05-26
EP4374921A2 (en) 2024-05-29
JP2021531294A (ja) 2021-11-18
MX2021000707A (es) 2021-03-25
WO2020018343A1 (en) 2020-01-23
CO2021000945A2 (es) 2021-02-17
BR112021000653A2 (pt) 2021-04-13
AU2019306477B2 (en) 2024-08-29
CN112469424A (zh) 2021-03-09
EP4374921A3 (en) 2024-06-19

Similar Documents

Publication Publication Date Title
EP3615057A4 (en) DOSING SCHEME FOR THE TREATMENT OF COGNITIVES AND MOTOR DISORDERS WITH BLOOD PLASMA AND BLOOD PLASMA PRODUCTS
EP3823636A4 (en) DOSAGE REGIMEN FOR THE TREATMENT OF COGNITIVE AND MOTOR IMPAIRMENTS WITH BLOOD PLASMA AND BLOOD PLASMA PRODUCTS
EP3370748A4 (en) THERAPEUTIC MICROBIOTA FOR THE TREATMENT AND / OR PREVENTION OF FOOD ALLERGY
EP3407918A4 (en) METHOD AND COMPOSITIONS FOR RNA-TREATED TREATMENT OF HIV INFECTIONS
EP3356521A4 (en) METHOD AND COMPOSITIONS FOR RNA-TREATED TREATMENT OF HIV INFECTIONS
EP3302709A4 (en) METHODS AND COMPOSITIONS RNA-GUIDED TREATMENT OF HIV INFECTIONS
EP3371306B8 (en) Materials and methods for treatment of hemoglobinopathies
EP3442600A4 (en) ADMINISTRATION OF B-SARCOGLYCAN AND MICROARN-29 USING AN ADENO-ASSOCIATED VIRUS VECTOR, AND TREATMENT OF MUSCLE DYSTROPHY
EP3684378A4 (en) GAPMERS AND THEIR USES IN THE TREATMENT OF MUSCLE DYSTROPHY
EP3570927A4 (en) MEDICAL PRODUCTS AND METHODS FOR THE CONTROLLED RELEASE OF NITROGEN OXIDE
EP3275482A4 (en) Syringe holder and medical solution administration set
EP3706736A4 (en) ASH1L DEGRADATION AGENTS AND METHODS OF TREATMENT THROUGH THEM
EP3707275A4 (en) DOSAGE AND STRATEGY RECOMMENDATIONS FOR THE TREATMENT OF MEDICAL CONDITIONS USING CANNABIS
EP4045036A4 (en) HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1-ASSOCIATED DISEASES
EP3253438A4 (en) Apparatus and methods for administering treatment within a bodily duct of a patient
EP3522900A4 (en) COMPOUNDS AND METHODS FOR DIAGNOSING AND TREATING VIRAL INFECTIONS
EP4073002A4 (en) DEVICE FOR TREATING LIQUIDS AND METHOD FOR TREATING LIQUIDS USING THIS DEVICE
EP3203996A4 (en) Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain
EP3490545A4 (en) METHODS OF MEDICAL TREATMENT WITH SUR1-TRPM4 CHANNEL INHIBITORS
EP3618923A4 (en) SYSTEM AND METHOD FOR TREATING MYOPIA
AU2017267955B2 (en) Reduced oxygen carriers and their use for the treatment of carboxyhemoglobinemia
EP3836936A4 (en) TREATMENT OF RECURRING FOLLICULAR LYMPHOMA
EP3220845A4 (en) Medical device for treatment of defective blood vessels, body cavities, and body ducts
EP3641795B8 (en) Methods and materials for treating blood vessels
EP4037684A4 (en) MEDICAL COGNITIVE TREATMENTS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210217

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20220311

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20220305BHEP

Ipc: A61K 38/38 20060101ALI20220305BHEP

Ipc: A61K 35/16 20150101AFI20220305BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221114

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E